INTRODUCTION: We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients. METHODS: We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score. RESULTS: There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: <5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and ≥5 years versus not use (HR, 1.89; 95% CI, 0.83-4.27). CONCLUSION: ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.
INTRODUCTION: We examined the association between androgen deprivation therapy (ADT) use and the risk of mild cognitive impairment (MCI) among prostate cancer patients. METHODS: We included 241 cognitively unimpaired men, aged 70 to 90, with a history of prostate cancer before enrollment in the population-based Mayo Clinic Study of Aging. Using the Rochester Epidemiology Project medical records-linkage system, ADT use and length of exposure were abstracted. Follow-up visits occurred every 15 months and MCI diagnoses were made based on clinical consensus. Cox proportional hazards models, with age as the timescale, were used to examine the association between ADT use (yes/no) and length of exposure with the risk of MCI adjusting for education, apolipoprotein E, depression, and the Charlson Index score. RESULTS: There was no association between any ADT use (27.8% of participants) and the risk of MCI in the multivariable model [hazard ratio (HR), 1.25; 95% confidence interval (CI), 0.75-2.10]. Although not significant, there was an ADT dose-response relationship for risk of MCI: <5 years versus no use (HR, 1.08; 95% CI, 0.60-1.96) and ≥5 years versus not use (HR, 1.89; 95% CI, 0.83-4.27). CONCLUSION: ADT use among prostate cancer patients was not associated with an increased risk of developing MCI.
Authors: Heather L McGinty; Kristin M Phillips; Heather S L Jim; Julie M Cessna; Yasmin Asvat; Mallory G Cases; Brent J Small; Paul B Jacobsen Journal: Support Care Cancer Date: 2014-05-25 Impact factor: 3.603
Authors: Shabbir M H Alibhai; Narhari Timilshina; Sarah Duff-Canning; Henriette Breunis; Ian F Tannock; Gary Naglie; Neil E Fleshner; Murray D Krahn; Padraig Warde; Shireen Marzouk; George A Tomlinson Journal: Cancer Date: 2016-09-01 Impact factor: 6.860
Authors: Rosebud O Roberts; Yonas E Geda; David S Knopman; Ruth H Cha; V Shane Pankratz; Bradley F Boeve; Robert J Ivnik; Eric G Tangalos; Ronald C Petersen; Walter A Rocca Journal: Neuroepidemiology Date: 2008-02-07 Impact factor: 3.282
Authors: Michelle M Mielke; Neelum T Aggarwal; Clara Vila-Castelar; Puja Agarwal; Eider M Arenaza-Urquijo; Benjamin Brett; Anna Brugulat-Serrat; Lyndsey E DuBose; Willem S Eikelboom; Jason Flatt; Nancy S Foldi; Sanne Franzen; Paola Gilsanz; Wei Li; Alison J McManus; Debora Melo van Lent; Sadaf Arefi Milani; C Elizabeth Shaaban; Shana D Stites; Erin Sundermann; Vidyani Suryadevara; Jean-Francoise Trani; Arlener D Turner; Jet M J Vonk; Yakeel T Quiroz; Ganesh M Babulal Journal: Alzheimers Dement Date: 2022-04-08 Impact factor: 16.655